1225 / 1578
Trials on targeted therapies for patients with BM
Entity
n Targeted Therapies Intracranial
response
rate
OS (months)
NSCLC BM; EGFR status unknown 23 Gefitinib
or erlotinib
73,9%
18,8
1-3 BSCLC BM; EGFR status
unknown
41 Erlotinib plus
WBRT and SRS
NA
6.1
NSCLC BM Alk rearrangement
27
5
Crizotinib
Crizotinib plus SRT
56,0%
65,0%
13,2 intra-
cranial TTP
HER2-positive breast cancer BM 45 Trastuzumab
(T-DM1
)
+chemo plus local
therapy
NA
26.8
Oligosymp. Her2-positiv breast BM 45 Laptinib plus
capecitabine
66,0%
17
BRAF mutated melanoma BM 74 Dabrafenib
39.2%
8,3
BRAF mutated melanoma BM 24 Vemurafenib
42,0%
5,3
Combined strategies may improve antitumor activity
Future of targeted therapy for BM